FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Amgen's Free Cash Flow for the
three
months ended in Dec. 2023 was $289 Mil. Amgen's Revenue for the
three
months ended in Dec. 2023 was $8,196 Mil. Therefore, Amgen's FCF Margin % for the quarter that ended in Dec. 2023 was 3.53%.
The historical rank and industry rank for Amgen's FCF Margin % or its related term are showing as below:
AMGN'
s FCF Margin % Range Over the Past 10 Years
Min: 26.11 Med: 39.26 Max: 46.01
Current: 26.11
During the past 13 years, the highest FCF Margin % of Amgen was 46.01%. The lowest was 26.11%. And the median was 39.26%.
AMGN's FCF Margin % is ranked better than 94.54% of 1026
companies
in the Drug Manufacturers industry
Industry Median: -0.68
vs AMGN: 26.11
Amgen FCF Margin % Historical Data
The historical data trend for Amgen's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Amgen's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen's FCF Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Amgen's FCF Margin % falls into.
Amgen FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Amgen's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen FCF Margin % Related Terms
Thank you for viewing the detailed overview of Amgen's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMGN has been successfully added to your 